替利霉素（HMR 3647）、左氧氟沙星及其他抗菌药物对人型支原体的比较活性
Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.
作者信息
Bebear C M, Renaudin H, Bryskier A, Bebear C
机构信息
Laboratoire de Bactériologie, Université Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France.
出版信息
Antimicrob Agents Chemother. 2000 Jul;44(7):1980-2. doi: 10.1128/AAC.44.7.1980-1982.2000.
Abstract
The activities of telithromycin and levofloxacin against 99 mycoplasma strains were compared to those of several macrolides, ofloxacin, and doxycycline. Telithromycin MICs of </=0.25 microgram/ml were found for all isolates, except for Mycoplasma hominis, while levofloxacin was active at concentrations of </=1 microgram/ml against all species studied.
摘要
将泰利霉素和左氧氟沙星对99株支原体菌株的活性与几种大环内酯类、氧氟沙星和多西环素进行了比较。除人型支原体外，所有分离株的泰利霉素最低抑菌浓度（MIC）均≤0.25微克/毫升，而左氧氟沙星对所有研究的菌种在浓度≤1微克/毫升时均有活性。
相似文献
1
Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas.替利霉素（HMR 3647）、左氧氟沙星及其他抗菌药物对人型支原体的比较活性
Antimicrob Agents Chemother. 2000 Jul;44(7):1980-2. doi: 10.1128/AAC.44.7.1980-1982.2000.
2
Comparative in vitro activity of telithromycin (HMR 3647), three macrolides, amoxycillin, cefdinir and levofloxacin against gram-positive clinical isolates in Japan.替利霉素（HMR 3647）、三种大环内酯类药物、阿莫西林、头孢地尼和左氧氟沙星对日本革兰氏阳性临床分离株的体外比较活性
J Antimicrob Chemother. 2000 Nov;46(5):797-802. doi: 10.1093/jac/46.5.797.
3
In vitro activities of ketolides HMR 3647 [correction of HRM 3647] and HMR 3004 [correction of HRM 3004], levofloxacin, and other quinolones and macrolides against Neisseria spp. and Moraxella catarrhalis.酮内酯类药物HMR 3647[应为HMR 3647]和HMR 3004[应为HMR 3004]、左氧氟沙星以及其他喹诺酮类和大环内酯类药物对奈瑟菌属和卡他莫拉菌的体外活性。
Antimicrob Agents Chemother. 1999 Apr;43(4):983-4. doi: 10.1128/AAC.43.4.983.
4
Comparison of the in vitro efficacy of telithromycin (HMR 3647) and levofloxacin with 22 antibiotic compounds against Bosea and Afipia species.
J Antimicrob Chemother. 2004 Apr;53(4):683-5. doi: 10.1093/jac/dkh115. Epub 2004 Mar 3.
5
Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.青霉素G、左氧氟沙星、莫西沙星、泰利霉素、普那霉素、奎奴普丁-达福普汀和利奈唑胺对左氧氟沙星中介及耐药肺炎链球菌的体外比较活性
Clin Microbiol Infect. 2002 Oct;8(10):680-3. doi: 10.1046/j.1469-0691.2002.00455.x.
6
Comparative in vitro susceptibilities of human mycoplasmas and ureaplasmas to a new investigational ketolide, CEM-101.人型支原体和脲原体对新型研究性酮内酯类药物CEM-101的体外敏感性比较
Antimicrob Agents Chemother. 2009 May;53(5):2139-41. doi: 10.1128/AAC.00090-09. Epub 2009 Mar 2.
7
Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis.左氧氟沙星、其他氟喹诺酮类、多西环素和红霉素对解脲脲原体和人型支原体的体外活性比较
J Antimicrob Chemother. 1999 Jun;43 Suppl C:33-6. doi: 10.1093/jac/43.suppl_3.33.
8
Comparative in vitro and bactericidal activities of telithromycin against penicillin-nonsusceptible, levofloxacin-resistant, and macrolide-resistant Streptococcus pneumoniae by time-kill methodology.采用时间杀菌法比较泰利霉素对青霉素不敏感、左氧氟沙星耐药及大环内酯类耐药肺炎链球菌的体外活性和杀菌活性。
Int J Antimicrob Agents. 2007 Mar;29(3):289-94. doi: 10.1016/j.ijantimicag.2006.09.024. Epub 2007 Jan 18.
9
In vitro activity of ketolides HMR 3004 and HMR 3647 and seven other antimicrobial agents against Corynebacterium diphtheriae.酮内酯类药物HMR 3004和HMR 3647以及其他七种抗菌药物对白喉棒状杆菌的体外活性
J Antimicrob Chemother. 2001 Jan;47(1):27-31. doi: 10.1093/jac/47.1.27.
10
Susceptibilities to telithromycin and six other agents and prevalence of macrolide resistance due to L4 ribosomal protein mutation among 992 Pneumococci from 10 central and Eastern European countries.来自10个中东欧国家的992株肺炎球菌对泰利霉素和其他六种药物的敏感性以及因L4核糖体蛋白突变导致的大环内酯类耐药性流行情况。
Antimicrob Agents Chemother. 2002 Feb;46(2):371-7. doi: 10.1128/AAC.46.2.371-377.2002.
引用本文的文献
1
Clinical and Microbiological Characterization of Bloodstream Infections Caused by Mycoplasma hominis: An Overlooked Pathogen.人型支原体引起的血流感染的临床和微生物学特征：一种被忽视的病原体
Infect Dis Ther. 2022 Jun;11(3):1003-1017. doi: 10.1007/s40121-022-00616-w. Epub 2022 Mar 14.
2
Community-acquired pneumonia related to intracellular pathogens.与细胞内病原体相关的社区获得性肺炎。
Intensive Care Med. 2016 Sep;42(9):1374-86. doi: 10.1007/s00134-016-4394-4. Epub 2016 Jun 8.
3
Mycoplasma genitalium: an emerging sexually transmitted pathogen.生殖道支原体：一种新兴的性传播病原体。
Indian J Med Res. 2012 Dec;136(6):942-55.
4
Mycoplasma genitalium: should we treat and how?生殖道支原体：我们是否应该治疗以及如何治疗？
Clin Infect Dis. 2011 Dec;53 Suppl 3(Suppl 3):S129-42. doi: 10.1093/cid/cir702.
5
6
Antibiotics for treatment of resistant gram-positive coccal infections.用于治疗耐革兰氏阳性球菌感染的抗生素。
Indian J Pediatr. 2006 Apr;73(4):323-34. doi: 10.1007/BF02825827.
7
Antibiotic susceptibility testing of Mycoplasma genitalium by TaqMan 5' nuclease real-time PCR.运用TaqMan 5'核酸酶实时PCR对生殖支原体进行抗生素敏感性测试。
Antimicrob Agents Chemother. 2005 Dec;49(12):4993-8. doi: 10.1128/AAC.49.12.4993-4998.2005.
8
Efficacy and safety of telithromycin 800 mg once daily for 7 days in community-acquired pneumonia: an open-label, multicenter study.每日一次服用800毫克泰利霉素，连续7天治疗社区获得性肺炎的疗效与安全性：一项开放标签、多中心研究。
BMC Infect Dis. 2005 May 31;5:43. doi: 10.1186/1471-2334-5-43.
9
Mycoplasma pneumoniae and its role as a human pathogen.肺炎支原体及其作为人类病原体的作用。
Clin Microbiol Rev. 2004 Oct;17(4):697-728, table of contents. doi: 10.1128/CMR.17.4.697-728.2004.
10
Telithromycin.泰利霉素
Drugs. 2004;64(15):1683-94; discussion 1695-6. doi: 10.2165/00003495-200464150-00006.
本文引用的文献
1
In vitro susceptibilities of Mycoplasma hominis to six fluoroquinolones as determined by E test.采用E试验法测定人型支原体对六种氟喹诺酮类药物的体外敏感性。
Antimicrob Agents Chemother. 1999 Oct;43(10):2571-3. doi: 10.1128/AAC.43.10.2571.
2
In-vitro antibacterial activity of levofloxacin against hospital isolates: a multicentre study.左氧氟沙星对医院分离菌株的体外抗菌活性：一项多中心研究。
J Antimicrob Chemother. 1999 Jun;43 Suppl C:43-50. doi: 10.1093/jac/43.suppl_3.43.
3
Comparative in-vitro activity of levofloxacin, other fluoroquinolones, doxycycline and erythromycin against Ureaplasma urealyticum and Mycoplasma hominis.左氧氟沙星、其他氟喹诺酮类、多西环素和红霉素对解脲脲原体和人型支原体的体外活性比较
J Antimicrob Chemother. 1999 Jun;43 Suppl C:33-6. doi: 10.1093/jac/43.suppl_3.33.
4
A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae.左氧氟沙星对肺炎链球菌体外活性的比较研究
J Antimicrob Chemother. 1999 Jun;43 Suppl C:5-8. doi: 10.1093/jac/43.suppl_3.5.
5
In-vitro activity of grepafloxacin, a new fluoroquinolone, against mycoplasmas.
J Antimicrob Chemother. 1999 May;43(5):711-4. doi: 10.1093/jac/43.5.711.
6
Mutations in the gyrA, parC, and parE genes associated with fluoroquinolone resistance in clinical isolates of Mycoplasma hominis.人型支原体临床分离株中与氟喹诺酮耐药相关的gyrA、parC和parE基因的突变
Antimicrob Agents Chemother. 1999 Apr;43(4):954-6. doi: 10.1128/AAC.43.4.954.
7
In vitro activities of two ketolides, HMR 3647 and HMR 3004, against gram-positive bacteria.两种酮内酯类药物HMR 3647和HMR 3004对革兰氏阳性菌的体外活性
Antimicrob Agents Chemother. 1999 Apr;43(4):930-6. doi: 10.1128/AAC.43.4.930.
8
In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas.新型氟喹诺酮类药物BAY 12 - 8039对支原体的体外活性
Antimicrob Agents Chemother. 1998 Mar;42(3):703-4. doi: 10.1128/AAC.42.3.703.
9
The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp.
J Antimicrob Chemother. 1997 Dec;40 Suppl A:31-4. doi: 10.1093/jac/40.suppl_1.31.
10
Antibiotic susceptibilities of mycoplasmas and treatment of mycoplasmal infections.支原体的抗生素敏感性及支原体感染的治疗
J Antimicrob Chemother. 1997 Nov;40(5):622-30. doi: 10.1093/jac/40.5.622.
Zotero 插件